Treatment of adult-onset still’s disease: up to date

References

• Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol. 2015;25:393–400.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
   PubMed Web of Science ®Google Scholar
• Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.
   PubMed Web of Science ®Google Scholar
• Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still’s disease. J Autoimmun. 2014;48-49:34–37.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–314.
   PubMed Web of Science ®Google Scholar
• Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still’s disease: a single center case series and comparison with literature. Semin Arthritis Rheum. 2016;45:711–716.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
   PubMed Web of Science ®Google Scholar
• Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.
   PubMed Web of Science ®Google Scholar
• Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013;72:1806–1812.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660.
   PubMed Web of Science ®Google Scholar
• Al-Homood IA. Biologic treatments for adult-onset Still’s disease. Rheumatology (Oxford). 2014;53:32–38.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Blanco R, Gonzalez-Gay MA. Adult-onset Still’s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44:309–314.
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–2535.
   PubMed Web of Science ®Google Scholar
• Schedel J, Bach B, Kummerle-Deschner JB, et al. [Autoinflammatory syndromes/fever syndromes]. Hautarzt. 2011;62:389-401; quiz 402.
   PubMed Web of Science ®Google Scholar
• Schoels MM, Van Der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583–589.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482–492.
   PubMed Web of Science ®Google Scholar
• Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11:12–20.
   PubMed Web of Science ®Google Scholar
• Fujii T, Akizuki M, Kameda H, et al. Methotrexate treatment in patients with adult onset Still’s disease–retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56:144–148.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag. 2015;11:33–43.
   PubMed Web of Science ®Google Scholar
• Manger B, Rech J, Schett G. Use of methotrexate in adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:S168–171.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lan JL, et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010;49:2305–2312.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis. 2004;63:1300–1306.
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–2427.
   PubMed Web of Science ®Google Scholar
• Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55:2237–2247.
   PubMed Web of Science ®Google Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159.
   PubMed Web of Science ®Google Scholar
• Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159:72–83.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Hot A, Huissoud C, et al. Adult-onset Still’s disease and pregnancy: about ten cases and review of the literature. Rheumatol Int. 2014;34:867–871.
   PubMed Web of Science ®Google Scholar
• Yang LTY, Shen Y, Wang L, et al. 17β-estradiol modulates the viability, phenotype, endocytosis, and inflammatory cytokine expression of RAW264.7 macrophages. Eur J Inflamm. 2016;14:8.
   Web of Science ®Google Scholar
• Pay S, Turkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–644.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Chao HC, Yan DC. Different articular outcomes of Still’s disease in Chinese children and adults. Clin Rheumatol. 2000;19:127–130.
   PubMed Web of Science ®Google Scholar
• Joung CI, Lee HS, Lee SW, et al. Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol. 2003;21:489–492.
   PubMed Web of Science ®Google Scholar
• Miller ML, Aaron S, Jackson J, et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 1985;28:146–150.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-onset still’s disease: from pathophysiology to targeted therapies. Int J Inflam. 2012;2012:879020.
   PubMedGoogle Scholar
• Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam. 2012;2012:819467.
   PubMedGoogle Scholar
• Liu QL, Huang L, Zhao QJ, et al. Relationship between serum interleukin-17 level and inflammatory bowel disease. J Biol Regul Homeost Agents. 2016;30:181–188.
   PubMed Web of Science ®Google Scholar
• Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66:2297–2307.
   PubMed Web of Science ®Google Scholar
• Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37:967–973.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim HS, Lee JS, et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still’s disease. J Rheumatol. 2012;39:2000–2007.
   PubMed Web of Science ®Google Scholar
• Wada T, Kanegane H, Ohta K, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74–78.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037–3046.
   PubMed Web of Science ®Google Scholar
• Rosario C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   PubMed Web of Science ®Google Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37:2369–2376.
   PubMed Web of Science ®Google Scholar
• Mehta B, Efthimiou P. Ferritin in adult-onset still’s disease: just a useful innocent bystander?. Int J Inflam. 2012;2012:298405.
   PubMedGoogle Scholar
• Jung KH, Kim JJ, Lee JS, et al. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol. 2014;43:162–169.
   PubMed Web of Science ®Google Scholar
• Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of Adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66:642–646.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev. 2015;14:429–437.
   PubMed Web of Science ®Google Scholar
• Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist’s repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford). 2015;54:231–240.
   PubMed Web of Science ®Google Scholar
• Bae CB, Suh CH, An JM, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2014;41:2403–2408.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Inokuma S, Matsubara E, et al. Serum beta2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease. Clin Rheumatol. 2013;32:999–1005.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol. 2015;11:749–761.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ciccia F, Cipriani P, et al. The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still’s disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. Clin Exp Immunol. 2016;183:397–404.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH, Sohn S, et al. Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash. Clin Rheumatol. 2016;35:1937–1942.
   PubMed Web of Science ®Google Scholar
• Han JH, Suh CH, Jung JY, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther. 2015;17:260.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther. 2014;16:423.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177–183.
   PubMed Web of Science ®Google Scholar
• Komiya A, Matsui T, Nogi S, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol. 2012;41:156–158.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Buyukasik Y, Akdogan A, et al. Increased serum vitamin B12 levels are associated with adult-onset Still’s disease with reactive macrophage activation syndrome. Joint Bone Spine. 2010;77:131–134.
   PubMed Web of Science ®Google Scholar
• Priori R, Ceccarelli F, Barone F, et al. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still’s disease. Clin Exp Rheumatol. 2008;26:933–937.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25:401–404.
   PubMed Web of Science ®Google Scholar
• Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34(Suppl 102):64–71.
   Google Scholar
• De Boysson H, Fevrier J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol. 2013;32:141–147.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Terajima H, Harigai M, et al. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheum. 2001;44:1716–1717.
   PubMed Web of Science ®Google Scholar
• Priori R, Barone F, Alessandri C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology (Oxford). 2011;50:776–780.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RW. Clinical characteristics, treatment, and outcome of adult onset Still’s disease in southern Chinese. J Rheumatol. 1998;25:2345–2351.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Sakamoto M, Yokota K, et al. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still’s disease. Intern Med. 2011;50:1757–1760.
   PubMed Web of Science ®Google Scholar
• Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–2357.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665. .
   PubMed Web of Science ®Google Scholar
• Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol. 2009;19:57–63.
   PubMed Web of Science ®Google Scholar
• Omagari K, Matsunaga Y, Yamashita H, et al. Successful treatment with cyclosporin in adult-onset Still disease manifesting as acute hepatitis with marked hyperferritinemia. Am J Med Sci. 2003;326:148–151.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–826.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–1689.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lv X, Tang G. Clinical features and prognosis of adult-onset Still’s disease: 75 cases from China. Int J Clin Exp Med. 2015;8:16634–16639.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ishii A, Oda A, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Case Rep Med. 2016;2016:5656320.
   Google Scholar
• Zhang Y, Yang Y, Bai Y, et al. Clinical characteristics and follow-up analysis of adult-onset Still’s disease complicated by hemophagocytic lymphohistiocytosis. Clin Rheumatol. 2016;35:1145–1151.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Iwanaga N, Adachi A, et al. Successful treatment with intravenous cyclophosphamide for refractory adult-onset still’s disease. Case Rep Rheumatol. 2015;2015:163952.
   PubMedGoogle Scholar
• Sayarlioglu M, Ucmak H, Ozkaya M, et al. Leflunomide and methotrexate combination in refractory adult-onset Still’s disease. Ann Pharmacother. 2007;41:1319–1320.
   PubMed Web of Science ®Google Scholar
• Cefle A. Leflunomide and azathioprine combination in refractory adult-onset Still’s disease. Ann Pharmacother. 2005;39:764–767.
   PubMed Web of Science ®Google Scholar
• Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295–298.
   PubMed Web of Science ®Google Scholar
• Jung JH, Jun JB, Yoo DH, et al. High toxicity of sulfasalazine in adult-onset Still’s disease. Clin Exp Rheumatol. 2000;18:245–248.
   PubMed Web of Science ®Google Scholar
• Saviola G, Benucci M, Abdi-Ali L, et al. Clarithromycin in adult-onset Still’s disease: a study of 6 cases. Rheumatol Int. 2010;30:555–560.
   PubMed Web of Science ®Google Scholar
• Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156–163.
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22:712–719.
   PubMed Web of Science ®Google Scholar
• Calamia KT. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adv Exp Med Biol. 2003;528:545–549.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–332.
   PubMed Web of Science ®Google Scholar
• Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55–57.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Dilhuydy MS, Vatan R, Etienne G, et al. Prolonged efficacy of infliximab for refractory adult-onset Still’s disease. Clin Exp Rheumatol. 2005;23:121–122.
   PubMed Web of Science ®Google Scholar
• Babacan T, Onat AM, Pehlivan Y, et al. Successful treatment of refractory adult Still’s disease and membranous glomerulonephritis with infliximab. Clin Rheumatol. 2010;29:423–426.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Ishii K, Iwakura M, et al. Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol. 2012;22:137–141.
   PubMed Web of Science ®Google Scholar
• Naniwa T, Tamechika S, Iwagaitsu S, et al. Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset still’s disease with liver failure with no response to tocilizumab therapy. Case Rep Rheumatol. 2013;2013:923497.
   PubMedGoogle Scholar
• Singh B, Biboa J, Musuku S, et al. Reversal of severe hepatitis with infliximab in adult-onset Still’s disease. Am J Med. 2013;126:e3–4.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51–57.
   PubMed Web of Science ®Google Scholar
• Diallo A, Mekinian A, Boukari L, et al. Severe hepatitis in a patient with adult-onset Still’s disease treated with anakinra. Rev Med Interne. 2013;34:168–170.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134–2144.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
   PubMed Web of Science ®Google Scholar
• Nordstrom D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008–2011.
   PubMed Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
   PubMed Web of Science ®Google Scholar
• Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308.
   PubMed Web of Science ®Google Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis. 2005;64:647–648.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–1803.
   PubMed Web of Science ®Google Scholar
• Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189–197.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–843.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Shimizu H, Hiraoka E, et al. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still’s disease. Mod Rheumatol. 2010;20:200–204.
   PubMed Web of Science ®Google Scholar
• Naumann L, Feist E, Natusch A, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset still's disease. Ann Rheum Dis. 2010;69:466–467.
   PubMed Web of Science ®Google Scholar
• Taylor SA, Vittorio JM, Martinez M, et al. Anakinra-induced acute liver failure in an adolescent patient with still’s disease. Pharmacotherapy. 2016;36:e1–4.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, De Vita S. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still’s disease. J Rheumatol. 2007;34:892–893.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–555.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sailler L, Astudillo L, et al. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol. 2010;29:1199–1200.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469–484.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Fautrel B. Anti-Interleukin-1 agents in adult onset still’s disease. Int J Inflam. 2012;2012:317820.
   PubMedGoogle Scholar
• Kuemmerle-Deschner JB, Hofer F, Endres T, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016;55:689–696.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133–142.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
   PubMed Web of Science ®Google Scholar
• Orrock JE, Ilowite NT. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2016;9:1015–1024.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201–205.
   PubMed Web of Science ®Google Scholar
• Barsotti S, Neri R, Iacopetti V, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol. 2014;20:121.
   PubMed Web of Science ®Google Scholar
• Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376–377.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15:R25.
   PubMed Web of Science ®Google Scholar
• Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–2579.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–2452.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533–541.
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr., Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876–884.
   PubMed Web of Science ®Google Scholar
• Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71:2056–2057.
   PubMed Web of Science ®Google Scholar
• Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013;45:357–363.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72:627–628.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–3389.
   PubMed Web of Science ®Google Scholar
• Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–159.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–247.
   PubMed Web of Science ®Google Scholar
• Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014;53:1352–1353.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–96.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17:336–340.
   PubMed Web of Science ®Google Scholar
• Tsuchida Y, Sumitomo S, Shoda H, et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2017;27:556–557.
   Web of Science ®Google Scholar
• Amenomori M, Migita K, Miyashita T, et al. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still’s disease. Clin Exp Rheumatol. 2005;23:100–102.
   PubMed Web of Science ®Google Scholar
• Altinok G, Levine M, Dhar JP, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Case Rep Rheumatol. 2016;26:297–301.
   Google Scholar
• Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol. 2016;26:297–301.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–294.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Reed GW, Solomon DH, et al. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016;18:280.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–876.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67:2759–2770.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:265–267.
   PubMed Web of Science ®Google Scholar
• Ostrowski RA, Tehrani R. Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17:315–317.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yoo WH. Rituximab for refractory adult-onset Still’s disease with thrombotic microangiopathy. Rheumatology (Oxford). 2014;53:1717–1718.
   PubMed Web of Science ®Google Scholar
• Belfeki N, Smiti Khanfir M, Said F, et al. Successful treatment of refractory adult onset Still’s disease with rituximab. Reumatismo. 2016;68:159–162.
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Jankowiak C, et al. Successful treatment of refractory adult onset Still’s disease with rituximab. Ann Rheum Dis. 2006;65:1117–1118.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–159.
   PubMed Web of Science ®Google Scholar
• Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still’s disease: a report of six patients and a review of the literature. Ann Rheum Dis. 2006;65:1596–1601.
   PubMed Web of Science ®Google Scholar
• Durand M, Troyanov Y, Laflamme P, et al. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37:879–880.
   PubMed Web of Science ®Google Scholar
• Grom AA. Mellins ED: macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22:561–566.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–298.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Minoia F, Davi S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a european league against rheumatism/american college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481–489.
   PubMed Web of Science ®Google Scholar
• Mehta MV, Manson DK, Horn EM, et al.. An atypical presentation of adult-onset Still’s disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature. Pulm Circ. 2016;6:136–142.
   PubMed Web of Science ®Google Scholar
• Park JH, Bae JH, Choi YS, et al. Adult-onset Still’s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci. 2004;19:137–141.
   PubMed Web of Science ®Google Scholar
• Barut K, Yucel G, Sinoplu AB, et al. Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period. Turk Pediatri Ars. 2015;50:206–210.
   PubMedGoogle Scholar
• Aytac S, Batu ED, Unal S, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int. 2016;36:1421–1429.
   PubMed Web of Science ®Google Scholar
• Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40:743–744.
   PubMed Web of Science ®Google Scholar
• Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine. 2013;80:653–655.
   PubMed Web of Science ®Google Scholar
• Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007;25:758–759.
   PubMed Web of Science ®Google Scholar
• Souabni L, Dridi L, Ben Abdelghani K, et al. Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset Still’s disease. Pan Afr Med J. 2014;17:94.
   PubMedGoogle Scholar
• Singh JA, Hossain A, Tanjong Ghogomu E, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13;(5):CD012183.
   Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J Biochem. 2015;158:173–179.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Connolly SE, Maldonado MA, et al. Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab. Arthritis Rheumatol. 2016;68:2083–2089.
   PubMed Web of Science ®Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. Plos One. 2013;8:e60635.
   PubMed Web of Science ®Google Scholar